Search
Grace Therapeutics, Inc
GRCEAdd to Watchlist
2.040USD
-0.060-2.86%
Close 10-08 16:00（ET）
33.19MMarket Cap
LossP/E TTM
Grace Therapeutics, Inc (GRCE) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Grace Therapeutics, Inc in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
6.000USD+189.86%
GRCE Analyst Recommendation Trends
In the current month, GRCE has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GRCE average Analyst price target in the last month is 6.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
GRCE Analyst Rating for Peer Comparison
Updated: Oct 8, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, GRCE EPS is projected to reach -0.150 in FY2027Q2, following reported EPS of -0.914 in FY2027Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
FY2027Q3
Forecast
-0.28
-0.23
-0.13
-0.15
-0.15
Actual
-0.14
-0.07
-0.91
--
--
Surprise
+51.18%
+70.32%
-603.31%
--
--
FAQs
What is Grace Therapeutics, Inc's price target?
Analysts forecast that Grace Therapeutics, Inc's price target is USD 6.00, with the highest forecast at USD 8.00 and the lowest forecast at USD 4.00.
How have Grace Therapeutics, IncGRCE's recent earnings per share performed?
The market expectation was USD -0.91, while Grace Therapeutics, IncGRCE's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.15.
What is the analyst rating for Grace Therapeutics, Inc?
Based on the ratings of Grace Therapeutics, Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.